Updated Nomogram Predicting Lymph Node Invasion i Undergoing Extended Pelvic Lymph Node Dissection: T Percentage of Positive Cores

European Urology 61, 480-487 DOI: 10.1016/j.eururo.2011.10.044

Citation Report

#	Article	IF	Citations
1	In Reply to Yu. International Journal of Radiation Oncology Biology Physics, 2012, 84, 301-302.	0.4	0
3	National Comprehensive Cancer Network Practice Guidelines 2011: Need for More Accurate Recommendations for Pelvic Lymph Node Dissection in Prostate Cancer. Journal of Urology, 2012, 188, 423-428.	0.2	23
4	Updated Nomogram Predicting Lymph Node Invasion in Patients with Prostate Cancer Undergoing Extended Pelvic Lymphadenectomy: Optimizing a Risk-Adapted Surgical Approach. European Urology, 2012, 61, 488-490.	0.9	3
5	Nodal Staging in Prostate Cancer: Still an Unresolved Issue. European Urology, 2012, 61, 1139-1141.	0.9	2
6	Robotic Extended Pelvic Lymphadenectomy for Intermediate- and High-Risk Prostate Cancer. European Urology, 2012, 61, 1004-1010.	0.9	56
7	External validation of the updated briganti nomogram to predict lymph node invasion in prostate cancer patients undergoing extended lymph node dissection. Prostate, 2013, 73, 211-218.	1.2	51
8	When to perform lymph node dissection in patients with renal cell carcinoma: a novel approach to the preoperative assessment of risk of lymph node invasion at surgery and of lymph node progression during followâ€up. BJU International, 2013, 112, E59-66.	1.3	42
9	Improved performance of SPECT-CT In-111 capromab pendetide by correlation with diffusion-weighted magnetic resonance imaging for identifying metastatic pelvic lymphadenopathy in prostate cancer. World Journal of Urology, 2013, 31, 1327-1332.	1.2	12
10	Assessing the most accurate formula to predict the risk of lymph node metastases from prostate cancer in contemporary patients treated with radical prostatectomy and extended pelvic lymph node dissection. Radiotherapy and Oncology, 2013, 109, 211-216.	0.3	18
11	Surgical Management of Prostate Cancer. Hematology/Oncology Clinics of North America, 2013, 27, 1111-1135.	0.9	11
12	Prostate cancer: ESMO Consensus Conference Guidelines 2012. Annals of Oncology, 2013, 24, 1141-1162.	0.6	137
13	Contemporary Issues in Radiotherapy for Clinically Localized Prostate Cancer. Hematology/Oncology Clinics of North America, 2013, 27, 1137-1162.	0.9	4
15	Pelvic Lymph Node Dissection in Prostate Cancer: The Mystery Is Taking Shape. European Urology, 2013, 63, 459-461.	0.9	16
16	Patterns of care and outcomes of radiotherapy for lymph node positivity after radical prostatectomy. BJU International, 2013, 111, 1208-1214.	1.3	35
17	Results of surgery for high-risk prostate cancer. Current Opinion in Urology, 2013, 23, 342-348.	0.9	20
18	Future prospects. Current Opinion in Urology, 2013, 23, 372-376.	0.9	2
19	External Validation of the Updated Nomogram Predicting Lymph Node Invasion in Patients with Prostate Cancer Undergoing Extended Pelvic Lymph Node Dissection. Urologia Internationalis, 2013, 90, 277-282.	0.6	27
20	Is pelvic lymph node dissection required at radical prostatectomy for lowâ€risk prostate cancer?. International Journal of Urology, 2013, 20, 1092-1096.	0.5	18

TION RE

#	Article	IF	CITATIONS
21	Controversies on individualized prostate cancer care: gaps in current practice. Therapeutic Advances in Urology, 2013, 5, 233-244.	0.9	6
22	Minimally invasive vs open radical prostatectomy in highâ€risk prostate cancer: comparing apples and pears?. BJU International, 2013, 112, 711-712.	1.3	1
23	The learning curve for laparoscopic extended pelvic lymphadenectomy for intermediate―and highâ€risk prostate cancer: implications for compliance with existing guidelines. BJU International, 2013, 112, 346-354.	1.3	21
24	Spatial distribution of positive cores improves the selection of patients with lowâ€risk prostate cancer as candidates for active surveillance. BJU International, 2013, 112, E234-42.	1.3	1
25	Extended vs standard lymph node dissection in robotâ€assisted radical prostatectomy for intermediate― or highâ€risk prostate cancer: a propensityâ€scoreâ€matching analysis. BJU International, 2013, 112, 216-223.	1.3	41
26	Standardized comparison of robotâ€essisted limited and extended pelvic lymphadenectomy for prostate cancer. BJU International, 2013, 112, 81-88.	1.3	63
28	Molecular and Functional Imaging for Detection of Lymph Node Metastases in Prostate Cancer. International Journal of Molecular Sciences, 2013, 14, 13842-13857.	1.8	28
29	Clinical nodal staging scores for prostate cancer: a proposal for preoperative risk assessment. British Journal of Cancer, 2014, 111, 213-219.	2.9	24
30	External Validation of the European Association of Urology Recommendations for Pelvic Lymph Node Dissection in Patients Treated with Robot-Assisted Radical Prostatectomy. Journal of Endourology, 2014, 28, 416-423.	1.1	33
31	Pathological analysis of lymph nodes in anterior prostatic fat excised at robot-assisted radical prostatectomy. Journal of Clinical Pathology, 2014, 67, 787-791.	1.0	15
32	How significant is upgrade in Gleason score between prostate biopsy and radical prostatectomy pathology while discussing less invasive treatment options?. Scandinavian Journal of Urology, 2014, 48, 177-182.	0.6	17
33	Cryosurgery for clinical <scp>T</scp> 3 prostate cancer. BJU International, 2014, 113, 684-685.	1.3	5
34	Yonsei nomogram to predict lymph node invasion in <scp>A</scp> sian men with prostate cancer during robotic era. BJU International, 2014, 113, 598-604.	1.3	11
35	Sentinel lymph node dissection in more than 1200 prostate cancer cases: Rate and prediction of lymph node involvement depending on preoperative tumor characteristics. International Journal of Urology, 2014, 21, 58-63.	0.5	39
36	Validation of Nomograms Predicting Lymph Node Involvement in Patients with Prostate Cancer Undergoing Extended Pelvic Lymph Node Dissection. Urologia Internationalis, 2014, 92, 300-305.	0.6	31
37	Contemporary minimallyâ€invasive extended pelvic lymph node dissection for prostate cancer before curative radiotherapy: Prospective standardized analysis of complications. International Journal of Urology, 2014, 21, 1138-1143.	0.5	10
38	Pelvic Lymph Node Dissection During Robot-assisted Radical Prostatectomy: Efficacy, Limitations, and Complications—A Systematic Review of the Literature. European Urology, 2014, 65, 7-16.	0.9	180
39	Comment je réalise un curage ilio-obturateur par voie cœlioscopique robot-assistée. Progrès En Urologie - FMC, 2014, 24, F36-F41.	0.2	0

#	Article	IF	Citations
40	Indication for and Extension of Pelvic Lymph Node Dissection During Robot-assisted Radical Prostatectomy: An Analysis of Five European Institutions. European Urology, 2014, 66, 635-643.	0.9	51
41	CEACAM5 is correlated with Angio/Lymphangiogenesis of Prostatic Lesions. Open Medicine (Poland), 2014, 9, 264-271.	0.6	1
42	The role of elective pelvic radiotherapy in clinically node-negative prostate cancer: A systematic review. Radiotherapy and Oncology, 2014, 110, 45-54.	0.3	20
43	Clinical and pathological nodal staging score for urothelial carcinoma of the bladder: an external validation. World Journal of Urology, 2014, 32, 365-371.	1.2	3
44	A systematic review and meta-analysis of comparative studies on the efficacy of extended pelvic lymph node dissection in patients with clinically localized prostatic carcinoma. Journal of Cancer Research and Clinical Oncology, 2014, 140, 243-256.	1.2	10
45	Prospective comparison of computed tomography, diffusion-weighted magnetic resonance imaging and [11C]choline positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer patients. European Journal of Nuclear Medicine and Molecular Imaging, 2014 41 694-701	3.3	79
46	Current status of pelvic lymph node dissection in prostate cancer. Journal of Robotic Surgery, 2014, 8, 1-6.	1.0	3
47	Can we improve the definition of highâ€risk, hormone naÃ⁻ve, nonâ€metastatic prostate cancer?. BJU International, 2014, 113, 189-199.	1.3	11
48	Multiparametric Magnetic Resonance Imaging in the Management and Diagnosis of Prostate Cancer: Current Applications and Strategies. Current Urology Reports, 2014, 15, 390.	1.0	24
49	Prostate Cancer Nomograms: A Review of Their Use in Cancer Detection and Treatment. Current Urology Reports, 2014, 15, 391.	1.0	22
50	EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent—Update 2013. European Urology, 2014, 65, 124-137.	0.9	1,613
51	Reply from Authors re: Francesco Montorsi, Giorgio Gandaglia. Sentinel Node Biopsy for Prostate Cancer: A Useless Surgical Exercise? Eur Urol 2014;66:999–1000. European Urology, 2014, 66, 1000-1001.	0.9	2
52	Sentinel Node Biopsy for Prostate Cancer: A Useless Surgical Exercise?. European Urology, 2014, 66, 999-1000.	0.9	0
53	Models of Assessment of Comparative Outcomes of Robot-Assisted Surgery. Urologic Clinics of North America, 2014, 41, 597-606.	0.8	6
54	Laparoscopic Sentinel Lymph Node Versus Hyperextensive Pelvic Dissection for Staging Clinically Localized Prostate Carcinoma: A Prospective Study of 200 Patients. Journal of Nuclear Medicine, 2014, 55, 753-758.	2.8	26
55	Sentinel lymph node dissection combined with meticulous histology increases the detection rate of nodal metastases in prostate cancer. International Urology and Nephrology, 2014, 46, 1543-1549.	0.6	21
56	Pathologic Nodal Staging Scores in Patients Treated with Radical Prostatectomy: A Postoperative Decision Tool. European Urology, 2014, 66, 439-446.	0.9	24
57	Does increasing the nodal yield improve outcomes in contemporary patients without nodal metastasis undergoing radical prostatectomy?. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 47.e1-47.e8.	0.8	8

#	Article	IF	CITATIONS
58	The Role of Radical Prostatectomy and Lymph Node Dissection in Lymph Node–Positive Prostate Cancer: A Systematic Review of the Literature. European Urology, 2014, 66, 191-199.	0.9	100
60	MP53-16 ONCOLOGIC OUTCOMES IN MEN WITH METASTASIS TO THE PROSTATIC ANTERIOR FAT PAD LYMPH NODES: A MULTI-INSTITUTION INTERNATIONAL STUDY. Journal of Urology, 2015, 193, .	0.2	0
61	Improving the surgical treatment of high-risk localised or locally advanced prostate cancer. Trends in Urology & Men's Health, 2015, 6, 29-32.	0.2	0
62	Importance of prostate volume in the stratification of patients with intermediateâ€risk prostate cancer. International Journal of Urology, 2015, 22, 555-561.	0.5	16
63	Extended pelvic lymph node dissection for clinically localized prostate cancer: a <scp>W</scp> est <scp>A</scp> ustralian experience. ANZ Journal of Surgery, 2015, 85, 936-940.	0.3	0
64	Extended pelvic lymph node dissection in patients with prostate cancer previously treated with surgery for lower urinary tract symptoms. BJU International, 2015, 116, 366-372.	1.3	4
65	Robot-Assisted Extended Pelvic Lymph Nodes Dissection for Prostate Cancer: Personal Surgical Technique and Outcomes. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2015, 41, 1209-1219.	0.7	13
66	Is Radical Perineal Prostatectomy a Viable Therapeutic Option for Intermediate- and High-risk Prostate Cancer?. Journal of Korean Medical Science, 2015, 30, 1631.	1.1	5
67	A clinicogenetic model to predict lymph node invasion by use of genome-based biomarkers from exome arrays in prostate cancer patients. Korean Journal of Urology, 2015, 56, 109.	1.2	3
68	First Nomogram Predicting the Probability of Lymph Node Involvement in Prostate Cancer Patients Undergoing Radioisotope Guided Sentinel Lymph Node Dissection. Urologia Internationalis, 2015, 95, 422-428.	0.6	18
69	Surgery for high-risk prostate cancer and metastatic prostate cancer. Current Problems in Cancer, 2015, 39, 33-40.	1.0	3
70	Utility of SPECT/CT scan for anatomical localization of pararectal and presacral sentinel nodes in prostate cancer. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2015, 34, 19-23.	0.1	3
71	Imaging biomarkers in prostate cancer: role of PET/CT and MRI. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 644-655.	3.3	57
72	The role of extended pelvic lymphadenectomy with radical prostatectomy for high-risk prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 208-216.	0.8	22
74	Added Value of Multiparametric Ultrasonography in Magnetic Resonance Imaging and Ultrasonography Fusion–guided Biopsy of the Prostate in Patients With Suspicion for Prostate Cancer. Urology, 2015, 86, 108-114.	0.5	34
75	Fluorescence Guided Targeted Pelvic Lymph Node Dissection for Intermediate and High Risk Prostate Cancer. Journal of Urology, 2015, 194, 357-363.	0.2	34
76	Association between Surgeon and Hospital Characteristics and Lymph Node Counts From Radical Prostatectomy and Pelvic Lymph Node Dissection. Urology, 2015, 85, 890-895.	0.5	11
77	PET/CT in prostate cancer. Medecine Nucleaire, 2015, 39, 54-58.	0.2	2

#	Article	IF	CITATIONS
78	Guidance on Patient Consultation. Current Evidence for Prostate-Specific Antigen Screening in Healthy Men and Treatment Options for Men with Proven Localised Prostate Cancer. Current Urology Reports, 2015, 16, 28.	1.0	1
79	Could Machine Learning Improve the Prediction of Pelvic Nodal Status of Prostate Cancer Patients? Preliminary Results of a Pilot Study. Cancer Investigation, 2015, 33, 232-240.	0.6	4
80	Robotic-assisted radical prostatectomy is less stressful than the open approach: results of a contemporary prospective study evaluating pathophysiology of cortisol stress-related kinetics in prostate cancer surgery. Journal of Robotic Surgery, 2015, 9, 249-255.	1.0	13
81	Adherence of the indication to European Association of Urology guideline recommended pelvic lymph node dissection at a high-volume center: Differences between open and robot-assisted radical prostatectomy. European Journal of Surgical Oncology, 2015, 41, 1547-1553.	0.5	13
82	Initial prostate cancer diagnosis and disease staging—the role of choline-PET–CT. Nature Reviews Urology, 2015, 12, 510-518.	1.9	34
83	Oncologic outcomes in men with metastasis to the prostatic anterior fat pad lymph nodes: a multi-institution international study. BMC Urology, 2015, 15, 79.	0.6	10
84	Prediction of Micrometastasis (< 1 cm) to Pelvic Lymph Nodes in Prostate Cancer: Role of Preoperative MRI. American Journal of Roentgenology, 2015, 205, W328-W334.	1.0	26
85	Nodal Occult Metastases in Intermediate- and High-Risk Prostate Cancer Patients Detected Using Serial Section, Immunohistochemistry, andÂReal-Time Reverse Transcriptase Polymerase Chain Reaction: Prospective Evaluation With Matched-Pair Analysis. Clinical Genitourinary Cancer, 2015, 13, e55-e64.	0.9	14
88	Pretreatment Tables Predicting Pathologic Stage of Locally Advanced Prostate Cancer. European Urology, 2015, 67, 319-325.	0.9	14
89	More Extensive Pelvic Lymph Node Dissection Improves Survival in Patients with Node-positive Prostate Cancer. European Urology, 2015, 67, 212-219.	0.9	178
91	What Evidence Do We Need to Support the Use of Extended Pelvic Lymph Node Dissection in Prostate Cancer?. European Urology, 2015, 67, 597-598.	0.9	18
92	Prostate-specific antigen nadir after high-dose-rate brachytherapy predicts long-term survival outcomes in high-risk prostate cancer. Journal of Contemporary Brachytherapy, 2016, 2, 95-103.	0.4	12
93	Sentinel lymph Node Detection during Radical Prostatectomy for Prostate Cancer: Current Evidence and Results of Our Experience. Urologia, 2016, 83, 124-129.	0.3	0
94	Current technique and results for extended pelvic lymph node dissection during robot-assisted radical prostatectomy. Investigative and Clinical Urology, 2016, 57, S155.	1.0	4
95	Robot assisted lymphadenectomy in urology: pelvic, retroperitoneal and inguinal. Minerva Urology and Nephrology, 2016, 69, 38-55.	1.3	12
96	Lymph node staging in prostate cancer: perspective for the pathologist. Journal of Clinical Pathology, 2016, 69, 1039-1045.	1.0	13
97	Comparing nodal versus bony metastatic spread using tumour phylogenies. Scientific Reports, 2016, 6, 33918.	1.6	19
99	Clinical significance of pelvic lymph node status in prostate cancer: review of 1690 cases. Internal and Emergency Medicine, 2016, 11, 399-404	1.0	7

#	Article	IF	CITATIONS
101	Validation of 3ÂT MRI including diffusion-weighted imaging for nodal staging of newly diagnosed intermediate- and high-risk prostate cancer. Clinical Radiology, 2016, 71, 328-334.	0.5	30
102	Rentabilidad diagnóstica y complicaciones de la linfadenectomÃa ampliada frente a la limitada asociada a prostatectomÃa radical. Actas Urológicas Españolas, 2016, 40, 75-81.	0.3	2
103	LinfadenectomÃa pélvica extendida en pacientes con cáncer de próstata clÃnicamente localizado: estudio observacional prospectivo. Actas Urológicas Españolas, 2016, 40, 446-452.	0.3	2
104	Determinants of long-term survival of patients with locally advanced prostate cancer: the role of extensive pelvic lymph node dissection. Prostate Cancer and Prostatic Diseases, 2016, 19, 63-67.	2.0	41
105	Indications for Pelvic Lymphadenectomy. , 2016, , 245-252.		0
106	The Role of Pelvic Lymph Node Dissection During Radical Prostatectomy in Patients With Gleason 6 Intermediate-risk Prostate Cancer. Urology, 2016, 93, 141-146.	0.5	7
107	PCUMex survey: Controversies in the management of prostate cancer among Mexican urologists. Revista Mexicana De Urologia, 2016, 76, 141-147.	0.0	0
108	PET/CT com Fluorocolinaâ€F18 no estadiamento inicial do carcinoma da próstata. Acta Urológica Portuguesa, 2016, 33, 87-97.	0.1	1
109	Extended pelvic lymphadenectomy in patients with clinically localized prostate cancer: A prospective observational study. Actas Urológicas Españolas (English Edition), 2016, 40, 446-452.	0.2	2
110	Current perspectives of sentinel lymph node dissection at the time of radical surgery for prostate cancer. Cancer Treatment Reviews, 2016, 50, 228-239.	3.4	12
111	Clinical significance of adding 3 Tesla MRI to the algorithm for decision making on neurovascular bundle preservation in radical prostatectomy. Japanese Journal of Clinical Oncology, 2016, 46, 1026-1030.	0.6	0
112	Lymph node dissection for renal cell carcinoma. Current Opinion in Urology, 2016, 26, 424-431.	0.9	11
113	Robotic assisted radical prostatectomy accelerates postoperative stress recovery: Final results of a contemporary prospective study assessing pathophysiology of cortisol peri-operative kinetics in prostate cancer surgery. Asian Journal of Urology, 2016, 3, 88-95.	0.5	16
114	Laparoscopic sentinel lymph node dissection in prostate cancer patients: the additional value depends on preoperative data. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1849-1856.	3.3	3
115	Indocyanine Green Guided Pelvic Lymph Node Dissection: An Efficient Technique to Classify the Lymph Node Status of Patients with Prostate Cancer Who Underwent Radical Prostatectomy. Journal of Urology, 2016, 196, 1429-1435.	0.2	36
116	Diagnostic yield and complications of extended lymphadenectomy versus limited lymphadenectomy combined with radical prostatectomy. Actas Urológicas Españolas (English Edition), 2016, 40, 75-81.	0.2	0
117	A nomogram for predicting the likelihood of lymph node metastasis in early gastric patients. BMC Cancer, 2016, 16, 92.	1.1	44
118	[â^²2]proPSA versus ultrasensitive PSA fluctuations over time in the first year from radical prostatectomy, in an high-risk prostate cancer population: A first report. BMC Urology, 2016, 16, 14.	0.6	4

#	Article	IF	CITATIONS
121	Risk Stratification of pN+ Prostate Cancer after Radical Prostatectomy from a Large Single Institutional Series with Long-Term Followup. Journal of Urology, 2016, 195, 1773-1778.	0.2	37
122	Clinical and Pathologic Staging of Prostate Cancer. , 2016, , 353-360.		Ο
123	The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients. European Urology, 2016, 69, 1142-1148.	0.9	60
124	Is there still a role for computed tomography and bone scintigraphy in prostate cancer staging? An analysis from the EUREKA-1 database. World Journal of Urology, 2016, 34, 517-523.	1.2	31
125	Outcome According to Elective Pelvic Radiation Therapy in Patients With High-Risk Localized Prostate Cancer: A Secondary Analysis of the GETUG 12 Phase 3 Randomized Trial. International Journal of Radiation Oncology Biology Physics, 2016, 94, 85-92.	0.4	28
127	Total Anatomical Reconstruction During Robot-assisted Radical Prostatectomy: Implications on Early Recovery of Urinary Continence. European Urology, 2016, 69, 485-495.	0.9	92
128	Primary Cryotherapy for High-Grade Clinically Localized Prostate Cancer: Oncologic and Functional Outcomes from the COLD Registry. Journal of Endourology, 2016, 30, 43-48.	1.1	30
129	Natural History of Clinical Recurrence Patterns of Lymph Node–Positive Prostate Cancer After Radical Prostatectomy. European Urology, 2016, 69, 135-142.	0.9	58
130	Update on histopathological evaluation of lymphadenectomy specimens from prostate cancer patients. World Journal of Urology, 2017, 35, 517-526.	1.2	16
131	Multispectral Fluorescence Imaging During Robot-assisted Laparoscopic Sentinel Node Biopsy: A First Step Towards a Fluorescence-based Anatomic Roadmap. European Urology, 2017, 72, 110-117.	0.9	51
132	Prospective evaluation of 68Galliumâ€prostateâ€specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer. BJU International, 2017, 119, 209-215.	1.3	263
133	Urethralâ€fixation technique improves early urinary continence recovery in patients who undergo retropubic radical prostatectomy. BJU International, 2017, 119, 245-253.	1.3	9
134	Clinical Applications of Molecular Imaging in the Management of Prostate Cancer. PET Clinics, 2017, 12, 185-192.	1.5	12
135	Vesico-urethral anastomosis (VUA) evaluation of short- and long-term outcome after robot-assisted laparoscopic radical prostatectomy (RARP): selective cystogram to improve outcome. Journal of Robotic Surgery, 2017, 11, 441-446.	1.0	5
136	Radiotherapy in the Management of Prostate Cancer. Medical Radiology, 2017, , 87-112.	0.0	0
137	Patterns of Pelvic Lymph Node Dissection at the Time of Radical Prostatectomy for Low-risk Men. Urology, 2017, 104, 143-149.	0.5	4
138	Is there a role for pure clinical prediction models in prostate cancer in the contemporary era?. BJU International, 2017, 119, 652-653.	1.3	0
139	Development and Internal Validation of a Novel Model to Identify the Candidates for Extended Pelvic Lymph Node Dissection in Prostate Cancer. European Urology, 2017, 72, 632-640.	0.9	165

#	Article	IF	CITATIONS
140	Propensity Score-Matched Comparison of Partial to Whole-Gland Cryotherapy for Intermediate-Risk Prostate Cancer: An Analysis of the Cryo On-Line Data Registry Data. Journal of Endourology, 2017, 31, 564-571.	1.1	30
142	Diagnostic Accuracy of 64 Copper Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Primary Lymph Node Staging of Intermediate- to High-risk Prostate Cancer: Our Preliminary Experience. Urology, 2017, 106, 139-145.	0.5	42
143	Radical Prostatectomy for High-risk Localized or Node-Positive Prostate Cancer: Removing the Primary. Current Urology Reports, 2017, 18, 53.	1.0	7
144	Plasma levels of intact and cleaved urokinase plasminogen activator receptor (uPAR) in men with clinically localised prostate cancer. Journal of Clinical Pathology, 2017, 70, 1063-1068.	1.0	1
145	PI-RADS version 2: Preoperative role in the detection of normal-sized pelvic lymph node metastasis in prostate cancer. European Journal of Radiology, 2017, 91, 22-28.	1.2	12
146	Clinical Factors Predicting and Stratifying the Risk of Lymph Node Invasion in Localized Prostate Cancer. Urologia Internationalis, 2017, 99, 207-214.	0.6	21
148	Beyond the Briganti nomogram: Individualisation of lymphadenectomy using selective sentinel node biopsy during radical prostatectomy for prostate cancer. Actas Urológicas Españolas (English) Tj ETQq0 0 0 rg	BTØ Q verlo	ckol 0 Tf 50 4
149	Development and external validation of a biopsyâ€derived nomogram to predict risk of ipsilateral extraprostatic extension. BJU International, 2017, 120, 76-82.	1.3	23
150	Improved decision making in intermediate-risk prostate cancer: a multicenter study on pathologic and oncologic outcomes after radical prostatectomy. World Journal of Urology, 2017, 35, 1191-1197.	1.2	10
151	Validation and head-to-head comparison of three nomograms predicting probability of lymph node invasion of prostate cancer in patients undergoing extended and/or sentinel lymph node dissection. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 2213-2226.	3.3	23
152	New surgical approaches for clinically high-risk or metastatic prostate cancer. Expert Review of Anticancer Therapy, 2017, 17, 1013-1031.	1.1	9
153	New aspects of molecular imaging in prostate cancer. Methods, 2017, 130, 36-41.	1.9	21
154	Assessing the Impact of Surgeon Experience on Urinary Continence Recovery After Robot-Assisted Radical Prostatectomy: Results of Four High-Volume Surgeons. Journal of Endourology, 2017, 31, 872-877.	1.1	43
155	Snail and Axin2 expression predict the malignant transformation of oral leukoplakia. Oral Oncology, 2017, 73, 48-55.	0.8	27
156	Clinical Factors Predicting Tumour Upgrading in Patients Under Active Surveillance and Elected to Active Treatment after Disease Reclassification or Progression. Urologia Internationalis, 2017, 99, 186-193.	0.6	2
157	Clinical Factors Predicting Bilateral Lymph Node Invasion in High-Risk Prostate Cancer. Urologia Internationalis, 2017, 99, 392-399.	0.6	20
158	Comparison between Briganti, Partin and MSKCC tools in predicting positive lymph nodes in prostate cancer: a systematic review and meta-analysis. Scandinavian Journal of Urology, 2017, 51, 345-350.	0.6	50
159	Performance characteristics of prostate-specific antigen density and biopsy core details to predict oncological outcome in patients with intermediate to high-risk prostate cancer underwent robot-assisted radical prostatectomy. BMC Urology, 2017, 17, 47.	0.6	6

#	Article	IF	CITATIONS
160	Sentinel Lymph Node Dissection to Select Clinically Node-negative Prostate Cancer Patients for Pelvic Radiation Therapy: Effect on Biochemical Recurrence and Systemic Progression. International Journal of Radiation Oncology Biology Physics, 2017, 97, 347-354.	0.4	17
161	Full Neurovascular Sparing Extraperitoneal Robotic Radical Prostatectomy: Our Experience with PERUSIA Technique. Journal of Endourology, 2017, 31, 32-37.	1.1	30
162	The New Prostate Cancer Grading System Does Not Improve Prediction of Clinical Recurrence After Radical Prostatectomy: Results of a Large, Two enter Validation Study. Prostate, 2017, 77, 263-273.	1.2	22
163	PET imaging for lymph node dissection in prostate cancer. World Journal of Urology, 2017, 35, 507-515.	1.2	9
164	The impact of local treatment of the primary tumor site in node positive and metastatic prostate cancer patients. Prostate Cancer and Prostatic Diseases, 2017, 20, 7-11.	2.0	11
165	Populationâ€Based External Validation of the Updated 2012 Partin Tables in Contemporary North American Prostate Cancer Patients. Prostate, 2017, 77, 105-113.	1.2	21
166	Tumor Volume and Clinical Failure in Highâ€Risk Prostate Cancer Patients Treated With Radical Prostatectomy. Prostate, 2017, 77, 3-9.	1.2	8
167	Patterns of Lymph Node Failure after Dose-escalated Radiotherapy: Implications for Extended Pelvic Lymph Node Coverage. European Urology, 2017, 71, 37-43.	0.9	64
168	EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. European Urology, 2017, 71, 618-629.	0.9	2,497
169	MÃ _i s allÃ _i del nomograma de Briganti: individualización de la linfadenectomÃa utilizando la biopsia selectiva del ganglio centinela durante la prostatectomÃa radical por cáncer de próstata. Actas Urológicas EspaA±olas, 2017, 41, 23-31.	0.3	1
170	Incidence and Predictors of 30-Day Readmission After Robot-Assisted Radical Prostatectomy. Clinical Genitourinary Cancer, 2017, 15, 67-71.	0.9	14
171	Prediction of pathological stage based on clinical stage, serum prostateâ€specific antigen, and biopsy Gleason score: Partin Tables in the contemporary era. BJU International, 2017, 119, 676-683.	1.3	86
172	Anogenital Distance, a Biomarker of Prenatal Androgen Exposure Is Associated With Prostate Cancer Severity. Prostate, 2017, 77, 406-411.	1.2	8
173	ls negative multiparametric magnetic resonance imaging really able to exclude significant prostate cancer? The realâ€life experience. BJU International, 2017, 119, 449-455.	1.3	36
174	Pelvic Lymph Node Dissection in Prostate Cancer: Indications, Extent and Tailored Approaches. Urologia, 2017, 84, 9-19.	0.3	25
175	Retropubic, Laparoscopic, and Robot-Assisted Radical Prostatectomy: A Comparative Analysis of the Surgical Outcomes in a Single Regional Center. Current Urology, 2017, 11, 36-41.	0.4	27
176	A population-based study of the clinical utility of 18F–choline PET/CT for primary metastasis staging of high-risk prostate cancer. European Journal of Hybrid Imaging, 2017, 1, .	0.6	2
177	Bilateral Lymph Node Micrometastases and Seminal Vesicle Invasion Associated with Same Clinical Predictors in Localized Prostate Cancer. Tumori, 2017, 103, 299-306.	0.6	24

#	Article	IF	CITATIONS
178	Updated Nomogram Incorporating Percentage of Positive Cores to Predict Probability of Lymph Node Invasion in Prostate Cancer Patients Undergoing Sentinel Lymph Node Dissection. Journal of Cancer, 2017, 8, 2692-2698.	1.2	21
179	Diagnostic performance of 68Gallium-PSMA-11 PET/CT to detect significant prostate cancer and comparison with 18FEC PET/CT. Oncotarget, 2017, 8, 111073-111083.	0.8	39
180	Surgeonâ€led prostate cancer lymph node staging: pathological outcomes stratified by robotâ€assisted dissection templates and patient selection. BJU International, 2018, 122, 66-75.	1.3	10
181	Extent of lymph node dissection improves survival in prostate cancer patients treated with radical prostatectomy without lymph node invasion. Prostate, 2018, 78, 469-475.	1.2	40
182	Indication to pelvic lymph nodes dissection for prostate cancer: the role of multiparametric magnetic resonance imaging when the risk of lymph nodes invasion according to Briganti updated nomogram is <5%. Prostate Cancer and Prostatic Diseases, 2018, 21, 85-91.	2.0	14
183	Multicenter evaluation of guideline adherence for pelvic lymph node dissection in patients undergoing open retropubic vs. laparoscopic or robot assisted radical prostatectomy according to the recent German S3 guideline on prostate cancer. World Journal of Urology, 2018, 36, 855-861.	1.2	8
184	Evaluating the predictive accuracy and the clinical benefit of a nomogram aimed to predict survival in nodeâ€positive prostate cancer patients: External validation on a multiâ€institutional database. International Journal of Urology, 2018, 25, 574-581.	0.5	8
185	3 + 4 = 6? Implications of the stratification of localized Gleason 7 prostate cancer by number and percentage of positive biopsy cores in selecting patients for active surveillance. Actas Urológicas Españolas (English Edition), 2018, 42, 103-113.	0.2	2
186	Lymph node dissection during radical prostatectomy for prostate cancer: extending the template in the right patients without increasing complications. BJU International, 2018, 121, 677-678.	1.3	3
187	Pair-matched patient-reported quality of life and early oncological control following focal irreversible electroporation versus robot-assisted radical prostatectomy. World Journal of Urology, 2018, 36, 1383-1389.	1.2	28
188	Androgen receptor moonlighting in the prostate cancer microenvironment. Endocrine-Related Cancer, 2018, 25, R331-R349.	1.6	18
189	Concordance of Cleason grading with three-dimensional ultrasound systematic biopsy and biopsy core pre-embedding. World Journal of Urology, 2018, 36, 863-869.	1.2	3
190	Preoperative multiparametric MRI of the prostate for the prediction of lymph node metastases in prostate cancer patients treated with extended pelvic lymph node dissection. European Radiology, 2018, 28, 1969-1976.	2.3	37
191	Sentinel lymph node surgery in prostate cancer using magnetic particles. Current Opinion in Urology, 2018, 28, 184-190.	0.9	5
192	Current status of theranostics in prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 471-495.	3.3	115
193	Adherence to pelvic lymph node dissection recommendations according to the National Comprehensive Cancer Network pelvic lymph node dissection guideline and the D'Amico lymph node invasion risk stratification. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 81.e17-81.e24.	0.8	18
194	Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part II: Recommended Approaches and Details of Specific Care Options. Journal of Urology, 2018, 199, 990-997.	0.2	279
195	Prostate-specific antigen associates with extensive lymph node invasion in high-risk prostate cancer. Tumori, 2018, 104, 307-311.	0.6	3

#	Article	IF	CITATIONS
196	Identification of curable high-risk prostate cancer using radical prostatectomy alone: who are the good candidates for undergoing radical prostatectomy among patients with high-risk prostate cancer?. International Journal of Clinical Oncology, 2018, 23, 757-764.	1.0	8
197	Comparison of nomograms predicting lymph node invasion in patients undergoing radical prostatectomy for prostate cancer. Irish Journal of Medical Science, 2018, 187, 33-37.	0.8	5
198	Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. European Urology, 2018, 73, 178-211.	0.9	488
199	Rate and Extent of Pelvic Lymph Node Dissection in the US Prostate Cancer Patients Treated With Radical Prostatectomy. Clinical Genitourinary Cancer, 2018, 16, e451-e467.	0.9	14
200	Identifying candidates for superâ€extended staging pelvic lymph node dissection among patients with highâ€risk prostate cancer. BJU International, 2018, 121, 421-427.	1.3	24
201	A novel tool for predicting extracapsular extension during graded partial nerve sparing in radical prostatectomy. BJU International, 2018, 121, 373-382.	1.3	40
202	¿3 + 4Â= 6? Implicaciones de la estratificación del cáncer de próstata localizado Gleason 7 por número y porcentaje de cilindros positivos de biopsia en la selección de pacientes para vigilancia activa. Actas Urológicas Españolas, 2018, 42, 103-113.	0.3	2
203	Lymphadenectomy in Gleason 7 prostate cancer: Adherence to guidelines and effect on clinical outcomes. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 13.e11-13.e18.	0.8	3
204	Delineating sites of failure following post-prostatectomy radiation treatment using 68 Ga-PSMA-PET. Radiotherapy and Oncology, 2018, 126, 244-248.	0.3	27
205	First North American validation and headâ€toâ€head comparison of four preoperative nomograms for prediction of lymph node invasion before radical prostatectomy. BJU International, 2018, 121, 592-599.	1.3	32
206	Prostate Specific Membrane Antigen Targeted ¹⁸ F-DCFPyL Positron Emission Tomography/Computerized Tomography for the Preoperative Staging of High Risk Prostate Cancer: Results of a Prospective, Phase II, Single Center Study. Journal of Urology, 2018, 199, 126-132.	0.2	86
208	Construction and external validation of a nomogram that predicts lymph node metastasis in early gastric cancer patients using preoperative parameters. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2018, 30, 623-632.	0.7	11
209	Developing a personalized template for lymph node dissection during radical prostatectomy. Translational Andrology and Urology, 2018, 7, S498-S504.	0.6	7
211	North American population-based validation of the National Comprehensive Cancer Network Practice Guideline Recommendations for locoregional lymph node and bone imaging in prostate cancer patients. British Journal of Cancer, 2018, 119, 1552-1556.	2.9	10
212	Comparison of Gleason upgrading rates in transrectal ultrasound systematic random biopsies versus US-MRI fusion biopsies for prostate cancer. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2018, 44, 1106-1113.	0.7	19
213	Current Imaging Techniques for Lymph Node Staging in Prostate Cancer: A Review. Frontiers in Surgery, 2018, 5, 74.	0.6	27
214	Extraperitoneal robot-assisted radical prostatectomy: a high-volume surgical center experience. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2018, 70, 479-485.	3.9	10
215	Sentinel lymph node imaging in urologic oncology. Translational Andrology and Urology, 2018, 7, 887-902.	0.6	21

#	Article	IF	CITATIONS
216	Pelvic Lymph Node Dissection for Prostate Cancer and Nomograms. , 2018, , 317-330.		0
217	Health Services Research and Robotic Surgery. , 2018, , 235-252.		0
219	Role of Prostate MRI in the Setting of Active Surveillance for Prostate Cancer. Advances in Experimental Medicine and Biology, 2018, 1096, 49-67.	0.8	1
221	Sentinel node evaluation in prostate cancer. Clinical and Experimental Metastasis, 2018, 35, 471-485.	1.7	11
222	Focal therapy for prostate cancer. Current Opinion in Urology, 2018, 28, 536-543.	0.9	9
225	Multispectral-Fluorescence Imaging as a Tool to Separate Healthy from Disease-Related Lymphatic Anatomy During Robot-Assisted Laparoscopy. Journal of Nuclear Medicine, 2018, 59, 1757-1760.	2.8	21
226	Dissecting the heterogeneity of localized prostate cancer risk groups through integration of percent of positive cores. Future Oncology, 2018, 14, 1469-1476.	1.1	0
227	Fluorescence-supported lymphography and extended pelvic lymph node dissection in robot-assisted radical prostatectomy: a prospective, randomized trial. World Journal of Urology, 2018, 36, 1817-1823.	1.2	39
228	One-Stop-Shop Whole-Body ⁶⁸ Ga-PSMA-11 PET/MRI Compared with Clinical Nomograms for Preoperative T and N Staging of High-Risk Prostate Cancer. Journal of Nuclear Medicine, 2018, 59, 1850-1856.	2.8	55
229	Sentinel lymph node dissection in prostate cancer using superparamagnetic particles of iron oxide: early clinical experience. International Urology and Nephrology, 2018, 50, 1427-1433.	0.6	4
230	Positive Association between Preoperative Total Testosterone Levels and Risk of Positive Surgical Margins by Prostate Cancer: Results in 476 Consecutive Patients Treated Only by Radical Prostatectomy. Urologia Internationalis, 2018, 101, 38-46.	0.6	27
231	Gaâ€68â€PSMA PET/CT in treatmentâ€naÃ⁻ve patients with prostate cancer: Which clinical parameters and risk stratification systems best predict PSMAâ€positive metastases?. Prostate, 2018, 78, 1103-1110.	1.2	15
232	Prostate Imaging-Reporting and Data System Version 2: Beyond Prostate Cancer Detection. Korean Journal of Radiology, 2018, 19, 193.	1.5	9
233	Radiotherapy for Prostate Cancer Patients with Pelvic Lymph Node Metastasis. , 2018, , 85-93.		0
234	Pelvic Lymphadenectomy for High-Risk Prostate Cancer. , 2018, , 41-49.		0
235	External Validation of Models Predicting the Probability of Lymph Node Involvement in Prostate Cancer Patients. European Urology Oncology, 2018, 1, 411-417.	2.6	31
236	Laparoscopic Radical Prostatectomy in Patients with High-Risk Prostate Cancer: Feasibility and Safety. Results of a Multicentric Study. Journal of Endourology, 2018, 32, 843-851.	1.1	3
237	Diagnostic accuracy of dual-energy CT-based nomograms to predict lymph node metastasis in gastric cancer. European Radiology, 2018, 28, 5241-5249.	2.3	68

#	Article	IF	CITATIONS
238	Preoperative Staging With 11C-Choline PET/CT Is Adequately Accurate in Patients With Very High-Risk Prostate Cancer. Clinical Genitourinary Cancer, 2018, 16, 305-312.e1.	0.9	19
239	Comparison Between 64Cu-PSMA-617 PET/CT and 18F-Choline PET/CT Imaging in Early Diagnosis of Prostate Cancer Biochemical Recurrence. Clinical Genitourinary Cancer, 2018, 16, 385-391.	0.9	33
240	Impact of multiparametric MRI and MRI-targeted biopsy on pre-therapeutic risk assessment in prostate cancer patients candidate for radical prostatectomy. World Journal of Urology, 2019, 37, 221-234.	1.2	25
241	Robot-assisted laparoscopic surgery using DROP-IN radioguidance: first-in-human translation. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 49-53.	3.3	65
242	Body mass index is an independent predictor of Clavien–Dindo grade 3 complications in patients undergoing robot assisted radical prostatectomy with extensive pelvic lymph node dissection. Journal of Robotic Surgery, 2019, 13, 83-89.	1.0	32
243	A machine learningâ€essisted decisionâ€support model to better identify patients with prostate cancer requiring an extended pelvic lymph node dissection. BJU International, 2019, 124, 972-983.	1.3	19
244	New approaches for effective and safe pelvic radiotherapy in high-risk prostate cancer. Nature Reviews Urology, 2019, 16, 523-538.	1.9	21
245	Development and characterization of a theranostic multimodal anti-PSMA targeting agent for imaging, surgical guidance, and targeted photodynamic therapy of PSMA-expressing tumors. Theranostics, 2019, 9, 2924-2938.	4.6	41
246	Imaging Diagnosis and Follow-up of Advanced Prostate Cancer: Clinical Perspectives and State of the Art. Radiology, 2019, 292, 273-286.	3.6	46
247	Prostate specific antigen (PSA) persistence 6 weeks after radical prostatectomy and pelvic lymph node dissection as predictive factor of radiographic progression in node-positive prostate cancer patients. Journal of Cancer, 2019, 10, 2237-2242.	1.2	15
248	Adverse pathology after radical prostatectomy: the prognostic role of cumulative cancer length >6-mm threshold in prostate cancer–positive biopsies. Prostate International, 2019, 7, 143-149.	1.2	5
249	Oncological Outcome After Radical Prostatectomy without Pelvic Lymph Node Dissection for Localized Prostate Cancer: Follow-up Results in a Single Institution. Cancer Investigation, 2019, 37, 524-530.	0.6	2
250	Positive Association between Preoperative Total Testosterone and Lymph Node Invasion in Intermediate Risk Prostate Cancer. Current Urology, 2019, 12, 216-222.	0.4	1
251	Diagnostic Accuracy of Magnetometer-Guided Sentinel Lymphadenectomy After Intraprostatic Injection of Superparamagnetic Iron Oxide Nanoparticles in Intermediate- and High-Risk Prostate Cancer Using the Magnetic Activity of Sentinel Nodes. Frontiers in Pharmacology, 2019, 10, 1123.	1.6	8
252	Total testosterone density predicts high tumor load and disease reclassification of prostate cancer: results in 144 low-risk patients who underwent radical prostatectomy. International Urology and Nephrology, 2019, 51, 2169-2180.	0.6	9
253	Surgeon volume and body mass index influence positive surgical margin risk after robot-assisted radical prostatectomy: Results in 732 cases. Arab Journal of Urology Arab Association of Urology, 2019, 17, 234-242.	0.7	6
254	Multimodality Imaging of Prostate Cancer. Journal of Nuclear Medicine, 2019, 60, 1350-1358.	2.8	51
255	Therapeutic approaches for lymph node involvement in prostate, bladder and kidney cancer. Expert Review of Anticancer Therapy, 2019, 19, 739-755.	1.1	8

#	ARTICLE	IF	CITATIONS
256	Biofluid quantification of TWEAK/Fn14 axis in combination with a selected biomarker panel improves assessment of prostate cancer aggressiveness. Journal of Translational Medicine, 2019, 17, 307.	1.8	8
257	High surgeon volume and positive surgical margins can predict the risk of biochemical recurrence after robot-assisted radical prostatectomy. Therapeutic Advances in Urology, 2019, 11, 175628721987828.	0.9	8
258	Radiomic features from PSMA PET for non-invasive intraprostatic tumor discrimination and characterization in patients with intermediate- and high-risk prostate cancer - a comparison study with histology reference. Theranostics, 2019, 9, 2595-2605.	4.6	105
259	Robot assisted radical prostatectomy in kidney transplant recipients: surgical, oncological and functional outcomes of two different robotic approaches. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2019, 45, 262-272.	0.7	19
260	Effect of Autologous Fibrin Glue on Lymphatic Drainage and Lymphocele Formation in Extended Bilateral Pelvic Lymphadenectomy in Robot-Assisted Radical Prostatectomy. Journal of Endourology, 2019, 33, 761-766.	1.1	10
261	Bleeding after prostatectomy: endovascular management. Gland Surgery, 2019, 8, 108-114.	0.5	3
262	Lymph Nodes Invasion of Marcille's Fossa Associates with High Metastatic Load in Prostate Cancer Patients Undergoing Extended Pelvic Lymph Node Dissection: The Role of "Marcillectomy― Urologia Internationalis, 2019, 103, 25-32.	0.6	28
263	Prostate Imaging Reporting and Data System in prostate cancer staging and planning for radical prostatectomy. Wideochirurgia I Inne Techniki Maloinwazyjne, 2019, 14, 262-270.	0.3	4
265	Reconsideration on Clinical Benefit of Pelvic Lymph Node Dissection during Radical Prostatectomy for Clinically Localized Prostate Cancer. Urologia Internationalis, 2019, 103, 125-136.	0.6	23
266	Role of MRI in planning radical prostatectomy: what is the added value?. World Journal of Urology, 2019, 37, 1289-1292.	1.2	26
267	Incidence, risk factors, and a predictive model for lymph node metastasis of submucosal (T1) colon cancer: A populationâ€based study. Journal of Digestive Diseases, 2019, 20, 288-293.	0.7	9
268	Extraprostatic Extension in Core Biopsies Epitomizes High-risk but Locally Treatable Prostate Cancer. European Urology Oncology, 2019, 2, 88-96.	2.6	7
269	Development and internal validation of a novel model and markers to identify the candidates for lymph node metastasis in patients with prostate cancer. Medicine (United States), 2019, 98, e16534.	0.4	7
271	A better way to predict lymph node involvement using machineâ€learning?. BJU International, 2019, 124, 901-902.	1.3	2
272	Pelvic lymph node dissection and its extent on survival benefit in prostate cancer patients with a risk of lymph node invasion >5%: a propensity score matching analysis from SEER database. Scientific Reports, 2019, 9, 17985.	1.6	19
273	The role of hypofractionated radiotherapy for the definitive treatment of localized prostate cancer: early results of a randomized trial. Journal of Cancer, 2019, 10, 6217-6224.	1.2	5
274	Incorporating mpMRI biopsy data into established pre-RP nomograms: potential impact of an increasingly common clinical scenario. Therapeutic Advances in Urology, 2019, 11, 175628721988280.	0.9	1
275	Nomograms in urologic oncology, advantages and disadvantages. Current Opinion in Urology, 2019, 29, 42-51.	0.9	27

#	Article	IF	CITATIONS
276	Current controversies on the role of lymphadenectomy for prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 219-226.	0.8	15
277	Is a Drain Needed After Robotic Radical Prostatectomy With or Without Pelvic Lymph Node Dissection? Results of a Single-Center Randomized Clinical Trial. Journal of Endourology, 2021, 35, 922-928.	1.1	18
278	Technologies for image-guided surgery for managing lymphatic metastases in prostate cancer. Nature Reviews Urology, 2019, 16, 159-171.	1.9	62
279	A Novel Nomogram to Identify Candidates for Extended Pelvic Lymph Node Dissection Among Patients with Clinically Localized Prostate Cancer Diagnosed with Magnetic Resonance Imaging-targeted and Systematic Biopsies. European Urology, 2019, 75, 506-514.	0.9	188
280	Pathologically Node-Positive Prostate Carcinoma – Prevalence, Pattern of Care and Outcome From a Population-Based Study. Clinical Oncology, 2019, 31, 91-98.	0.6	5
281	Stateâ€ofâ€theâ€art imaging techniques in the management of preoperative staging and reâ€staging of prostate cancer. International Journal of Urology, 2019, 26, 18-30.	0.5	16
282	A Head-to-head Comparison of Four Prognostic Models for Prediction of Lymph Node Invasion in African American and Caucasian Individuals. European Urology Focus, 2019, 5, 449-456.	1.6	11
283	Role of Bed Assistant During Robot-assisted Radical Prostatectomy: The Effect of Learning Curve on Perioperative Variables. European Urology Focus, 2020, 6, 397-403.	1.6	6
284	Early Catheter Removal After Robot-assisted Radical Prostatectomy: Results from a Prospective Single-institutional Randomized Trial (Ripreca Study). European Urology Focus, 2020, 6, 259-266.	1.6	13
285	Risk factors of positive surgical margins after robot-assisted radical prostatectomy in high-volume center: results in 732 cases. Journal of Robotic Surgery, 2020, 14, 167-175.	1.0	20
286	Sensitivity and specificity of Briganti nomogram in Turkish patients undergoing radical prostatectomy and pelvic lymph node dissection. Aging Male, 2020, 23, 836-840.	0.9	3
287	Retrograde Release of the Neurovascular Bundle with Preservation of Dorsal Venous Complex During Robot-assisted Radical Prostatectomy: Optimizing Functional Outcomes. European Urology, 2020, 77, 628-635.	0.9	54
288	Significance of examined lymph-node count in accurate staging and long-term survival in patients undergoing radical prostatectomy: a population-based study. International Urology and Nephrology, 2020, 52, 271-278.	0.6	4
289	Prostate-Specific Membrane Antigen PET/CT Combined with Sentinel Node Biopsy for Primary Lymph Node Staging in Prostate Cancer. Journal of Nuclear Medicine, 2020, 61, 540-545.	2.8	40
290	Comparison between Zumsteg classification and Briganti nomogram for the risk of lymph-node invasion before radical prostatectomy. World Journal of Urology, 2020, 38, 1719-1727.	1.2	1
291	Preoperative PI-RADS Version 2 scores helps improve accuracy of clinical nomograms for predicting pelvic lymph node metastasis at radical prostatectomy. Prostate Cancer and Prostatic Diseases, 2020, 23, 116-126.	2.0	13
293	Visualization of peri-prostatic neurovascular fibers before and after radical prostatectomy by means of diffusion tensor imaging (DTI) with clinical correlations: preliminary report. Journal of Robotic Surgery, 2020, 14, 357-363.	1.0	7
294	Lymph Node Involvement in Treatment-NaÃ ⁻ ve Prostate Cancer Patients: Correlation of PSMA PET/CT Imaging and Roach Formula in 280 Men in Radiotherapeutic Management. Journal of Nuclear Medicine, 2020, 61, 46-50.	2.8	26

#	Article	IF	CITATIONS
295	68Ca-PSMA-11 PET has the potential to improve patient selection for extended pelvic lymph node dissection in intermediate to high-risk prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 147-159.	3.3	43
296	Biopsy Grade Group as a reliable prognostic factor for BCR in Afro-Caribbean men with intermediate- and high-risk prostate cancer. World Journal of Urology, 2020, 38, 1493-1499.	1.2	0
297	Can Intraoperative Fluorescence Imaging Identify All Lesions While the Road Map Created by Preoperative Nuclear Imaging Is Masked?. Journal of Nuclear Medicine, 2020, 61, 834-841.	2.8	24
298	Imaging and T Category for Prostate Cancer in the 8th Edition of the Union for International Cancer Control TNM Classification. European Urology Oncology, 2020, 3, 563-564.	2.6	7
299	Development and external validation of a nomogram to predict lymph node invasion after robot assisted radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 37.e11-37.e20.	0.8	5
300	Linear extent of positive surgical margin impacts biochemical recurrence after robot-assisted radical prostatectomy in a high-volume center. Journal of Robotic Surgery, 2020, 14, 663-675.	1.0	11
301	Questioning the Status Quo: Should Gleason Grade Group 1 Prostate Cancer be Considered a "Negative Core―in Pre-Radical Prostatectomy Risk Nomograms? An International Multicenter Analysis. Urology, 2020, 137, 102-107.	0.5	2
302	Establishment of Decision Rules and Risk Assessment Model for Preoperative Prediction of Lymph Node Metastasis in Gastric Cancer. Frontiers in Oncology, 2020, 10, 1638.	1.3	11
303	Development of a nomogram predicting metastatic disease and the assessment of NCCN, AUA and EAU guideline recommendations for bone imaging in prostate cancer patients. World Journal of Urology, 2021, 39, 1815-1823.	1.2	6
304	Extended pelvic lymphâ€node dissection is independently associated with improved overall survival in patients with prostate cancer at highâ€risk of lymphâ€node invasion. BJU International, 2020, 125, 756-758.	1.3	7
305	Changing the Goal Posts: Prostate-specific Membrane Antigen Targeted Theranostics in Prostate Cancer. Seminars in Oncology Nursing, 2020, 36, 151052.	0.7	3
306	Whether extended pelvic lymph node dissection should be performed in prostate cancer: The present evidence from a systematic review and metaâ€analysis. Precision Medical Sciences, 2020, 9, 23-30.	0.1	2
307	Survival Outcomes of Radical Prostatectomy + Extended Pelvic Lymph Node Dissection and Radiotherapy in Prostate Cancer Patients With a Risk of Lymph Node Invasion Over 5%: A Population-Based Analysis. Frontiers in Oncology, 2020, 10, 607576.	1.3	4
309	Development of a novel nomogram incorporating platelet-to-lymphocyte ratio for the prediction of lymph node involvement in prostate carcinoma. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 930.e1-930.e6.	0.8	4
310	Robot-assisted radical prostatectomy with clipless intrafascial neurovascular bundle-sparing approach: surgical technique and one-year functional and oncologic outcomes. Scientific Reports, 2020, 10, 17595.	1.6	3
311	Current status of PSMA PET imaging in prostate cancer. Asia-Pacific Journal of Clinical Oncology, 2020, 16, 7-11.	0.7	3
312	Robotic perineal radical prostatectomy in a patient with a pre-existing three piece inflatable penile prosthesis. Aktuelle Urologie, 2020, , .	0.3	1
313	The Role of 68Ga-PSMA Positron Emission Tomography/Computerized Tomography for Preoperative Lymph Node Staging in Intermediate/High Risk Patients With Prostate Cancer: A Diagnostic	1.3	16

#	Article	IF	CITATIONS
314	Clinical impact of PET imaging in prostate cancer management. Current Opinion in Urology, 2020, Publish Ahead of Print, 649-653.	0.9	1
315	External validation of the Briganti nomogram predicting lymph node invasion in patients with intermediate and high-risk prostate cancer diagnosed with magnetic resonance imaging-targeted and systematic biopsies: A European multicenter study. Urologic Oncology: Seminars and Original Investigations. 2020. 38. 847.e9-847.e16.	0.8	11
316	Association between Basal Total Testosterone Levels and Prostate Cancer D'Amico Risk Classes. Urologia Internationalis, 2020, 104, 716-723.	0.6	2
317	Analysis of Learning Curve in Robot-Assisted Radical Prostatectomy Performed by a Surgeon. Advances in Urology, 2020, 2020, 1-7.	0.6	6
318	Laparoscopic radical prostatectomy and extended pelvic lymph node dissection: a combined technique. Wideochirurgia I Inne Techniki Maloinwazyjne, 2020, 15, 192-198.	0.3	4
319	Development and validation of hub genes for lymph node metastasis in patients with prostate cancer. Journal of Cellular and Molecular Medicine, 2020, 24, 4402-4414.	1.6	19
320	Can we predict the development of symptomatic lymphocele following robot-assisted radical prostatectomy and lymph node dissection? Results from a tertiary referral Centre. Scandinavian Journal of Urology, 2020, 54, 328-333.	0.6	9
321	The impact of extended pelvic lymph node dissection on the risk of hospital readmission within 180Âdays after robot assisted radical prostatectomy. World Journal of Urology, 2020, 38, 2799-2809.	1.2	14
322	Predictive Factors of the Risk of Long-Term Hospital Readmission after Primary Prostate Surgery at a Single Tertiary Referral Center: Preliminary Report. Urologia Internationalis, 2020, 104, 465-475.	0.6	8
323	Role of Para-aortic Radiotherapy in the Management of Prostate Cancer. Clinical Oncology, 2020, 32, 189-198.	0.6	10
324	Late results of a randomized trial on the role of mild hypofractionated radiotherapy for the treatment of localized prostate cancer. Journal of Cancer, 2020, 11, 1008-1016.	1.2	3
325	Urologic Robotic Surgery. Surgical Clinics of North America, 2020, 100, 361-378.	0.5	35
326	External Validation of the 2019 Briganti Nomogram for the Identification of Prostate Cancer Patients Who Should Be Considered for an Extended Pelvic Lymph Node Dissection. European Urology, 2020, 78, 138-142.	0.9	55
327	Robotic Perineal Radical Prostatectomy: Initial Experience with the da Vinci Si Robotic System. Urologia Internationalis, 2020, 104, 710-715.	0.6	12
328	Trends in risk-group distribution and Pentafecta outcomes in patients treated with nerve-sparing, robot-assisted radical prostatectomy: a 10-year low-intermediate volume single-center experience. World Journal of Urology, 2021, 39, 389-397.	1.2	5
329	Pathological features of prostate cancer in men treated with robot-assisted radical prostatectomy in the Middle East. Journal of Robotic Surgery, 2021, 15, 125-133.	1.0	4
330	Peri-prostatic adipose tissue measurements using MRI predict prostate cancer aggressiveness in men undergoing radical prostatectomy. Journal of Endocrinological Investigation, 2021, 44, 287-296.	1.8	8
331	External evaluation of the Briganti nomogram to predict lymph node metastases in intermediate-risk prostate cancer patients. World Journal of Urology, 2021, 39, 1489-1497.	1.2	5

#	Article	IF	CITATIONS
332	EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer—2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. European Urology, 2021, 79, 243-262.	0.9	1,545
333	How radical prostatectomy procedures have changed over the last 10Âyears in Italy: a comparative analysis based on more than 1500 patients participating in the MIRROR-SIU/LUNA and the Pros-IT CNR study. World Journal of Urology, 2021, 39, 1445-1452.	1.2	0
335	Evaluating F-18-PSMA-1007-PET in primary prostate cancer and comparing it to multi-parametric MRI and histopathology. Prostate Cancer and Prostatic Diseases, 2021, 24, 423-430.	2.0	37
336	Cribriform architecture prostatic adenocarcinoma in needle biopsies is a strong independent predictor for lymph node metastases in radical prostatectomy. European Journal of Cancer, 2021, 148, 432-439.	1.3	13
337	Extended Versus Limited Pelvic Lymph Node Dissection During Radical Prostatectomy for Intermediate- and High-risk Prostate Cancer: Early Oncological Outcomes from a Randomized Phase 3 Trial. European Urology, 2021, 79, 595-604.	0.9	111
338	Current and emerging therapies for localized high-risk prostate cancer. Expert Review of Anticancer Therapy, 2021, 21, 267-282.	1.1	3
339	A DROP-IN Gamma Probe for Robot-assisted Radioguided Surgery of Lymph Nodes During Radical Prostatectomy. European Urology, 2021, 79, 124-132.	0.9	58
340	Optimizing the risk threshold of lymph node involvement for performing extended pelvic lymph node dissection in prostate cancer patients: a cost-effectiveness analysis. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 72.e7-72.e14.	0.8	1
341	Pathologic nodal downstaging in men with clinically involved lymph nodes undergoing radical prostatectomy: Implications for definitive locoregional therapy. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 130.e1-130.e7.	0.8	0
342	Indications for and complications of pelvic lymph node dissection in prostate cancer: accuracy of available nomograms for the prediction of lymph node invasion. BJU International, 2021, 127, 318-325.	1.3	28
343	Robotic radical perineal prostatectomy: tradition and evolution in the robotic era. Current Opinion in Urology, 2021, 31, 11-17.	0.9	10
344	Oncologic outcome of radical prostatectomy versus radiotherapy as primary treatment for high and very high risk localized prostate cancer. Prostate, 2021, 81, 223-230.	1.2	6
346	Predicting Gleason sum upgrading from biopsy to radical prostatectomy pathology: a new nomogram and its internal validation. BMC Urology, 2021, 21, 3.	0.6	7
347	Recommendations on robotic-assisted radical prostatectomy: a Brazilian experts' consensus. Journal of Robotic Surgery, 2021, 15, 829-839.	1.0	1
348	Predictors of complications occurring after open and robot-assisted prostate cancer surgery: a retrospective evaluation of 1062 consecutive patients treated in a tertiary referral high volume center. Journal of Robotic Surgery, 2022, 16, 45-52.	1.0	6
349	Diagnostic Value, Oncologic Outcomes, and Safety Profile of Image-Guided Surgery Technologies During Robot-Assisted Lymph Node Dissection with Sentinel Node Biopsy for Prostate Cancer. Journal of Nuclear Medicine, 2021, 62, 1363-1371.	2.8	36
350	Effects of pre-emptive pregabalin and multimodal anesthesia on postoperative opioid requirements in patients undergoing robot-assisted laparoscopic prostatectomy. BMC Urology, 2021, 21, 14.	0.6	2
351	Benefit of a more extended pelvic lymph node dissection among patients undergoing radical prostatectomy for localized prostate cancer: A causal mediation analysis. Prostate, 2021, 81, 286-294.	1.2	4

#	Article	IF	CITATIONS
" 352	Indocyanine green guidance improves the efficiency of extended pelvic lymph node dissection during laparoscopic radical prostatectomy. International Journal of Urology, 2021, 28, 566-572.	0.5	14
353	Advanced Imaging Analysis in Prostate MRI: Building a Radiomic Signature to Predict Tumor Aggressiveness. Diagnostics, 2021, 11, 594.	1.3	17
354	Should Peritoneal Re-Approximation be Performed After Transperitoneal Robot-Assisted Radical Prostatectomy?. Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A, 2021, , .	0.5	0
355	Nomograms in Urologic Oncology: Lights and Shadows. Journal of Clinical Medicine, 2021, 10, 980.	1.0	13
356	Head-to-Head Comparison of Two Nomograms Predicting Probability of Lymph Node Invasion in Prostate Cancer and the Therapeutic Impact of Higher Nomogram Threshold. Journal of Clinical Medicine, 2021, 10, 999.	1.0	8
357	Impact of Pelvic Lymph Node Dissection and Its Extent on Perioperative Morbidity in Patients Undergoing Radical Prostatectomy for Prostate Cancer: A Comprehensive Systematic Review and Meta-analysis. European Urology Oncology, 2021, 4, 134-149.	2.6	55
358	Comparison of Perioperative, Oncological, and Functional Outcomes of Three-Dimensional Versus Robot-Assisted Laparoscopic Radical Prostatectomy: A Preliminary Study. Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A, 2021, , .	0.5	3
359	A genomic-clinicopathologic Nomogram for the preoperative prediction of lymph node metastasis in gastric cancer. BMC Cancer, 2021, 21, 455.	1.1	5
360	Novel anatomical apical dissection utilizing puboprostatic "open-collar―technique: Impact on apical surgical margin and early continence recovery. PLoS ONE, 2021, 16, e0249991.	1.1	2
361	Reconstruction of the ligamentous apparatus of the lower pelvis in robot-assisted radical prostatectomy as a stage of the learning curve. Andrologia I Genital'naa Hirurgia, 2021, 22, 76-84.	0.1	0
362	The Establishment of New Thresholds for PLND-Validated Clinical Nomograms to Predict Non-Regional Lymph Node Metastases: Using 68Ga-PSMA PET/CT as References. Frontiers in Oncology, 2021, 11, 658669.	1.3	4
363	A Genomic-Clinicopathologic Nomogram for the Prediction of Lymph Node Invasion in Prostate Cancer. Journal of Oncology, 2021, 2021, 1-14.	0.6	4
364	Still Unanswered: The Role of Extended Pelvic Lymphadenectomy in Improving Oncological Outcomes in Prostate Cancer. European Urology, 2021, 79, 605-606.	0.9	5
365	Deep learning approach to predict lymph node metastasis directly from primary tumour histology in prostate cancer. BJU International, 2021, 128, 352-360.	1.3	37
366	Clinical parameters and nomograms for predicting lymph node metastasis detected with ⁶⁸ Gaâ€PSMAâ€PET/CT in prostate cancer patients candidate to definitive radiotherapy. Prostate, 2021, 81, 648-656.	1.2	6
367	External Validation of the Briganti Nomogram to Predict Lymph Node Invasion in Prostate Cancer—Setting a New Threshold Value. Life, 2021, 11, 479.	1.1	5
368	Extraperitoneal Laparoscopic Versus Transperitoneal Robot-Assisted Laparoscopic Approaches for Extended Pelvic Lymph Node Dissection During Radical Prostatectomy. Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A, 2021, , .	0.5	3
369	68Ga-PSMA-11 PET, 18F-PSMA-1007 PET, and MRI for Gross Tumor Volume Delineation in Primary Prostate Cancer: Intermodality and Intertracer Variability. Practical Radiation Oncology, 2021, 11, 202-211.	1.1	13

#	Article	IF	CITATIONS
370	External validation of the Memorial Sloan Kettering Cancer Centre and Briganti nomograms for the prediction of lymph node involvement of prostate cancer using clinical stage assessed by magnetic resonance imaging. BJU International, 2021, 128, 236-243.	1.3	10
371	Re: Jean F.P. Lestingi, Giuliano B. Guglielmetti, Quoc-Dien Trinh, et al. Extended Versus Limited Pelvic Lymph Node Dissection During Radical Prostatectomy for Intermediate- and High-risk Prostate Cancer: Early Oncological Outcomes from a Randomized Phase 3 Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.11.040. European Urology. 2021. 79. e154-e156.	0.9	1
372	The role of pre-biopsy mpMRI in lymph node staging for prostate cancer. Urologia, 2022, 89, 64-69.	0.3	0
373	External validation of the Briganti 2019 nomogram to identify candidates for extended pelvic lymph node dissection among patients with high-risk clinically localized prostate cancer. International Journal of Clinical Oncology, 2021, 261, 1736-1744. Reply to Alberta Brigant, Giorgio Candaglia, Markus Graefen, Steven Ioniau, R. Jeffrey Karnes, and	1.0	4
374	Francesco Montorsi〙s Letter to the Editor re: Jean F.P. Lestingi, Giuliano B. Guglielmetti, Quoc-Dien Trinh, et al. Extended Versus Limited Pelvic Lymph Node Dissection During Radical Prostatectomy for Intermediate- and High-risk Prostate Cancer: Early Oncological Outcomes from a Randomized Phase 3 Trial. Eur Urol 2021;79:595–604. Time for a Change? Clinically Meaningful Reasons Why We Will	0.9	0
375	Continue Performin. European Urology, 2021, 79, e184-e185. Integration of clinicopathologic identification and deep transferrable image feature representation improves predictions of lymph node metastasis in prostate cancer. EBioMedicine, 2021, 68, 103395.	2.7	19
376	Predicting early outcomes in patients with intermediate―and highâ€risk prostate cancer using prostateâ€specific membrane antigen positron emission tomography and magnetic resonance imaging. BJU International, 2022, 129, 54-62.	1.3	10
377	Functional outcomes rather than complications predict poor health-related quality of life at 6Âmonths after robot-assisted radical prostatectomy. Journal of Robotic Surgery, 2022, 16, 453-462.	1.0	1
378	[18F]-Fluciclovine PET/CT for preoperative nodal staging in high-risk primary prostate cancer: final results of a prospective trial. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 49, 390-409.	3.3	7
379	Analysis of Prostate Cancer Tumor Microenvironment Identifies Reduced Stromal CD4 Effector T-cell Infiltration in Tumors with Pelvic Nodal Metastasis. European Urology Open Science, 2021, 29, 19-29.	0.2	6
380	Low endogenous testosterone levels are associated with the extend of lymphnodal invasion at radical prostatectomy and extended pelvic lymph node dissection. International Urology and Nephrology, 2021, 53, 2027-2039.	0.6	10
381	The prognostic value of digital rectal exam for the existence of advanced pathologic features after prostatectomy. Prostate, 2021, 81, 1064-1070.	1.2	3
384	How accurate is 68Gallium-prostate specific membrane antigen positron emission tomography / computed tomography (68Ga-PSMA PET/CT) on primary lymph node staging before radical prostatectomy in intermediate and high risk prostate cancer? A study of patient- and lymph node- based analyses. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 6.e1-6.e9.	0.8	4
385	A Combined Technology to Protect the Anatomic Integrity of Distal Urethral Sphincter Complex in Radical Prostatectomy Improves Early Urinary Continence Recovery Without Sacrifice of Oncological Outcomes. Frontiers in Oncology, 2021, 11, 711093.	1.3	1
386	Assessment of MYC/PTEN Status by Gene-Protein Assay in Grade Group 2 Prostate Biopsies. Journal of Molecular Diagnostics, 2021, 23, 1030-1041.	1.2	3
387	Risk Stratification of Patients Candidate to Radical Prostatectomy Based on Clinical and Multiparametric Magnetic Resonance Imaging Parameters: Development and External Validation of Novel Risk Groups. European Urology, 2022, 81, 193-203.	0.9	30
388	On the probability of lymph node negativity in pN0-staged prostate cancer—aÂtheoretically derived rule of thumb for adjuvant needs. Strahlentherapie Und Onkologie, 2022, 198, 690-699.	1.0	1
389	Associations between LncRNA MALAT1 Polymorphisms and Lymph Node Metastasis in Prostate Cancer. Diagnostics, 2021, 11, 1692.	1.3	10

ARTICLE IF CITATIONS Therapeutic Consequences of Omitting a Pelvic Lymph Node Dissection at Radical Prostatectomy when 390 0.5 2 Grade and/or Stage Increase. Urology, 2021, 155, 144-151. Comparative results of nerve-sparing robotic-assisted prostatectomy. Andrologia I Genital'naa 0.1 Hirurgia, 2021, 22, 44-48. Combination MRI-targeted and systematic prostate biopsy may overestimate gleason grade on final 392 surgical pathology and impact risk stratification. Urologic Oncology: Seminars and Original 0.8 7 Investigations, 2022, 40, 59.e1-59.e5. Development and Validation of Models to Predict Pathological Outcomes of Radical Prostatectomy in 0.2 Regional and National Cohorts. Journal of Urology, 2022, 207, 358-366. Management of Localized and Locally Advanced Prostate Cancer., 2020, , 579-590. 394 1 Endogenous testosterone mirrors prostate cancer aggressiveness: correlation between basal testosterone serum levels and prostate cancer European Urology Association clinical risk classes in a large cohort of Caucasian patients. International Urology and Nephrology, 2020, 52, 1261-1269. Interobserver agreement of [68Ga]Ga-PSMA-11 PET/CT images interpretation in men with newly 398 1.1 14 diagnosed prostate cancer. EJNMMI Research, 2020, 10, 15. A nomogram composed of clinicopathologic features and preoperative serum tumor markers to 0.8 16 predict lymph node metastasis in early gastric cancer patients. Oncotarget, 2016, 7, 59630-59639. SOX2 boosts major tumor progression genes in prostate cancer and is a functional biomarker of 400 0.8 49 lymph node metastasis. Oncotarget, 2016, 7, 12372-12385. Benefits of Elective Para-Aortic Radiotherapy for pN1 Prostate Cancer Using Arc Therapy (Intensity-Modulated or Volumetric Modulated Arc Therapy): Protocol for a Nonrandomized Phase II Trial. JMIR Research Protocols, 2018, 7, e11256. Extended pelvic lymphadenectomy for prostate cancer: should the Cloquet's nodes dissection be considered only an option?. Minerva Urologica E Nefrologica = the Italian Journal of Urology and 402 3.9 27 Nephrology, 2019, 71, 136-145. Body Mass Index and prostatic-specific antigen are predictors of prostate cancer metastases in patients undergoing robot-assisted radical prostatectomy and extended pelvic lymph node dissection. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2019, 71, 516-523. Extended pelvic lymph node dissection during radical prostatectomy: comparison between initial robotic experience of a high-volume open surgeon and his contemporary open series. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2019, 71, 597-604. 404 3.9 3 Reliability of the different versions of Partin tables in predicting extraprostatic extension of prostate cancer: a systematic review and meta-analysis. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2019, 71, 457-478. Open approach, extended pelvic lymph node dissection, and seminal vesicle invasion are independent 406 predictors of hospital readmission after prostate cancer surgery: a large retrospective study. 9 3.9 Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2020, 72, 72-81. Near-infrared fluorescence and nuclear imaging and targeting of prostate cancer. Translational Andrology and Urology, 2013, 2, 254-264. Extended lymph node dissection in robotic radical prostatectomy: Current status. Indian Journal of 408 0.2 1 Urology, 2016, 32, 109. Assessment of the performance of Partin's nomogram (2007) in contemporary Indian cohort. Indian Journal of Urology, 2016, 32, 199.

#	Article	IF	CITATIONS
410	High body mass index predicts multiple prostate cancer lymph node metastases after radical prostatectomy and extended pelvic lymph node dissection. Asian Journal of Andrology, 2020, 22, 323.	0.8	32
411	Robotic perineal radical prostatectomy and robotic pelvic lymph node dissection via a perineal approach: The Tugcu Bakirkoy Technique. Turkish Journal of Urology, 2018, 44, 114-118.	1.3	15
412	Comparison of surgical, oncological, and functional outcomes of robot-assisted and laparoscopic radical prostatectomy in patients with prostate cancer. Turkish Journal of Urology, 2019, 45, 410-417.	1.3	10
413	The effect of peritoneal re-approximation on lymphocele formation in transperitoneal robot-assisted radical prostatectomy and extended pelvic lymphadenectomy. Turkish Journal of Urology, 2020, 46, 460-467.	1.3	11
414	External validation of Memorial Sloan Kettering Cancer Center nomogram and prediction of optimal candidate for lymph node dissection in clinically localized prostate cancer. Central European Journal of Urology, 2020, 73, 19-25.	0.2	7
415	Sentinel lymph node biopsy in renal malignancy: The past, present and future. World Journal of Nephrology, 2016, 5, 182.	0.8	8
416	Guidelines for radiotherapy of prostate cancer (2020 edition). Precision Radiation Oncology, 2021, 5, 160-182.	0.4	8
417	The role of surgery as active treatment for high risk localized prostate cancer seen from an epidemiological perspective. OA Epidemiology, 2013, 1, .	0.2	0
419	Pelvic Lymphadenectomy for Prostate and Bladder Cancer. , 2015, , 69-78.		0
420	Results and Outcomes of Radical Prostatectomy for Low-Risk Prostate Cancer in North African Ethnic Group. World Journal of Nephrology and Urology, 2015, 4, 251-255.	0.3	0
422	The Evolution of Sentinel Node Biopsy in Urological Malignancy. Cancer Research Frontiers, 2015, 1, 25-36.	0.2	0
423	Pelvic Lymph Node Dissection: Open Benchmarks with Lymphoscintigraphy. , 2016, , 131-142.		0
424	Rationale of Surgery in Locally Advanced and Oligometastatic Prostate Cancer. The Korean Journal of Urological Oncology, 2016, 14, 97-108.	0.1	0
425	Primästaging des Prostatakarzinoms. , 2017, , 111-137.		0
426	Management of Prostate Cancer. , 2017, , 19-26.		0
427	Utilization of pelvic lymph node dissection in patients undergoing robot-assisted radical prostatectomy in India versus the United States – A Vattikuti Collective Quality Initiative database analysis. Indian Journal of Cancer, 2017, 54, 421.	0.2	1
429	Radical Prostatectomy in the Metastatic Setting. , 2018, , 169-184.		0
431	The Treatments for Low-Risk Prostate Cancer. The Korean Journal of Urological Oncology, 2019, 17, 7-21.	0.1	0

#	Article	IF	CITATIONS
432	The Treatments for Intermediate Risk Prostate Cancer. The Korean Journal of Urological Oncology, 2019, 17, 22-33.	0.1	0
433	Treatment of Patients With High Risk Prostate Cancer. The Korean Journal of Urological Oncology, 2019, 17, 34-47.	0.1	Ο
434	The role of side-specific biopsy and dominant tumor location at radical prostatectomy in predicting the side of nodal metastases in organ confined prostate cancer: is lymphatic spread really unpredictable?. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2019, 71, 146-153.	3.9	2
435	T Staging and Target Volume Definition by Imaging in GU Tumors. Medical Radiology, 2020, , 221-254.	0.0	0
436	THE COMBINATION OF EXTERNAL RADIATION THERAPY WITH HIGH DOSE RATE BRAHYTERAPY BOOST FOR PROSTATE CANCER: A COMPARATIVE CHARACTERISTIC OF TWO FRACTION MODES. Siberian Journal of Oncology, 2020, 19, 40-49.	0.1	0
437	Radikal Prostatektomide Eksize Edilen Anterior Prostatik Yağ Dokuda Lenf Nodu Metastazını Predikte Eden Faktörler. Harran Üniversitesi Tıp Fakültesi Dergisi, 0, , 289-293.	0.1	0
438	Radiomics for Identification and Prediction in Metastatic Prostate Cancer: A Review of Studies. Frontiers in Oncology, 2021, 11, 771787.	1.3	23
439	Embarking with laparoscopic radical prostatectomy and dealing with the complications and collateral problems: A single-center experience. Turkish Journal of Urology, 2020, 46, 37-43.	1.3	1
440	A narrative review of pelvic lymph node dissection in prostate cancer. Translational Andrology and Urology, 2020, 9, 3049-3055.	0.6	9
441	Should We Reconsider the Necessity of a Refinement of Prostate Cancer Risk Classification and Radiotherapy Treatment Strategy? Experiences from a Retrospective Analysis of Data from a Single Institution. Journal of Clinical Medicine, 2021, 10, 110.	1.0	0
442	Prostatakarzinom: Onkologische Kennzeichen. Springer Reference Medizin, 2020, , 1-18.	0.0	0
443	Some ways of improvement of detection of hormone-naive non-metastatic high-risk prostate cancer. Urology, 2020, 24, .	0.1	0
444	The impact of drainage pathways on the detection of nodal metastases in prostate cancer: a phase II randomized comparison of intratumoral vs intraprostatic tracer injection for sentinel node detection. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 1743-1753.	3.3	13
445	Nomogram for predicting lymph node metastasis rate of submucosal gastric cancer by analyzing clinicopathological characteristics associated with lymph node metastasis. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2015, 27, 572-9.	0.7	5
447	Magnetometer-Guided Sentinel Lymph Node Dissection in Prostate Cancer: Rate of Lymph Node Involvement Compared with Radioisotope Marking. Cancers, 2021, 13, 5821.	1.7	5
448	The detection rate of apical tumour involvement on preoperative MRI and its impact on clinical outcomes in patients with localized prostate cancer. Journal of Robotic Surgery, 2022, 16, 1047-1056.	1.0	3
449	Development of a Radiomic-Based Model Predicting Lymph Node Involvement in Prostate Cancer Patients. Cancers, 2021, 13, 5672.	1.7	14
450	Multimodal imaging of prostate cancer. PoÄki, 2020, 9, 68-79.	0.1	0

#	Article	IF	CITATIONS
451	Pelvic lymph node dissection using indocyanine green fluorescence lymphangiography in robotic assisted radical prostatectomy for non-lymph node or distant metastasis prostate cancer patients. Urological Science, 2021, 32, 27.	0.2	0
452	Mapping of Recurrence Sites Following Adjuvant or Salvage Radiotherapy for Prostate Cancer Patients. Frontiers in Oncology, 2021, 11, 787347.	1.3	7
453	Schwannoma: A rare cause of false-positive 68Ga-PSMA PET/CT uptake in the evaluation of metastatic prostate cancer. Urology Case Reports, 2022, 41, 101974.	0.1	1
454	A â€~real-world' standard for radical prostatectomy: Analysis of the British Association of Urological Surgeons Complex Operations Reports, 2016–2018. Journal of Clinical Urology, 0, , 205141582110639.	0.1	0
455	Development and validation of a prognostic nomogram for 2018 FIGO stages IB1, IB2, and IIA1 cervical cancer: a large multicenter study. Annals of Translational Medicine, 2022, 10, 121-121.	0.7	2
456	Preoperative Predictors of Lymph Node Invasion and Biochemical Recurrence in High-risk Prostate Cancer. Cancer Diagnosis & Prognosis, 2022, 2, 49-54.	0.3	4
457	Up- and downgrading in single intermediate-risk positive biopsy core prostate cancer. Prostate International, 2022, 10, 21-27.	1.2	3
458	Prognostic Genomic Tissue-Based Biomarkers in the Treatment of Localized Prostate Cancer. Journal of Personalized Medicine, 2022, 12, 65.	1.1	3
459	Pelvic lymph node dissection in high-risk prostate cancer. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2022, 48, 54-66.	0.7	6
460	Extent of pelvic lymph node dissection improves early oncological outcomes for patients with high-risk prostate cancer without lymph node involvement after robot-assisted radical prostatectomy. International Journal of Clinical Oncology, 2022, 27, 781-789.	1.0	3
462	A Nomogram Predicting Lymph Node Metastasis in Patients with Prostate Cancer Undergoing Ultrasound-Guided Transrectal Prostate Biopsy. Indian Journal of Surgery, 2022, 84, 1217-1224.	0.2	1
463	Validation of models predicting lymph node involvement probability in patients with prostate cancer. International Journal of Urology, 2022, 29, 428-434.	0.5	6
465	Identifying the Candidates Who Will Benefit From Extended Pelvic Lymph Node Dissection at Radical Prostatectomy Among Patients With Prostate Cancer. Frontiers in Oncology, 2021, 11, 790183.	1.3	3
466	High-Intensity Focused-Ultrasound Focal Therapy Versus Laparoscopic Radical Prostatectomy: A Comparison of Oncological and Functional Outcomes in Low- and Intermediate-Risk Prostate Cancer Patients. Journal of Personalized Medicine, 2022, 12, 251.	1.1	5
467	Gamma camera imaging of sentinel node in prostate cancer. , 2022, , .		0
468	External Validation and Comparison of Two Nomograms Predicting the Probability of Lymph Node Involvement in Patients subjected to Robot-Assisted Radical Prostatectomy and Concomitant Lymph Node Dissection: A Single Tertiary Center Experience in the MRI-Era. Frontiers in Surgery, 2022, 9, 829515	0.6	2
469	Nonâ€organ confined stage and upgrading rates in exclusive PSA highâ€risk prostate cancer patients. Prostate, 2022, 82, 687-694.	1.2	3
471	Multiparametric MRI-based radiomics model to predict pelvic lymph node invasion for patients with prostate cancer. European Radiology, 2022, 32, 5688-5699.	2.3	15

#	Article	IF	CITATIONS
472	Pelvic Lymph Node Dissection at Radical Prostatectomy for Intermediate Risk Prostate Cancer: Assessing Utility and Nodal Metastases Within a Statewide Quality Improvement Consortium. Urology, 2022, , .	0.5	0
473	Predictive ability of prebiopsy magnetic resonance imaging and biopsy for sideâ€specific negative lymph node metastasis at radical prostatectomy. Prostate, 2022, , .	1.2	1
474	Simplified urethral score system for predicting complex anterior urethroplasty. Actas Urológicas Españolas (English Edition), 2022, , .	0.2	0
475	Robot-assisted radical prostatectomy in the treatment of patients with clinically high-risk localized and locally advanced prostate cancer: single surgeons functional and oncologic outcomes. BMC Urology, 2022, 22, 49.	0.6	6
476	Effect of prostate and bony pelvic dimensions measured by preoperative magnetic resonance imaging on robot-assisted radical prostatectomy. Journal of Robotic Surgery, 2022, 16, 1483-1489.	1.0	1
477	Application of One-Step Nucleic Acid Amplification (OSNA) in different cancer entities and usefulness in prostate cancer: a systematic review. BMC Cancer, 2022, 22, 357.	1.1	0
478	The role of pelvic lymphadenectomy in the treatment of prostate cancer. Urologie Pro Praxi, 2021, 22, 133-138.	0.0	0
479	A novel robust nomogram based on preoperative hemoglobin and albumin levels and lymphocyte and platelet counts (HALP) for predicting lymph node metastasis of gastric cancer. Journal of Gastrointestinal Oncology, 2021, 12, 2706-2718.	0.6	10
480	Nomograms Involving HER2 for Predicting Lymph Node Metastasis in Early Gastric Cancer. Frontiers in Cell and Developmental Biology, 2021, 9, 781824.	1.8	9
481	Preoperative MRI Plâ€RADS scores are associated with prostate cancer upstaging on surgical pathology. Prostate, 2022, 82, 352-358.	1.2	3
482	A Clinicopathological Feature-Based Nomogram for Predicting the Likelihood of D3 Lymph Node Metastasis In Right-Sided Colon Cancer Patients. Diseases of the Colon and Rectum, 2021, Publish Ahead of Print, .	0.7	1
483	Influence of Biopsy Gleason Score on the Risk of Lymph Node Invasion in Patients With Intermediate-Risk Prostate Cancer Undergoing Radical Prostatectomy. Frontiers in Surgery, 2021, 8, 759070.	0.6	1
484	Clinical Trial Protocol for PSMA-SELECT: A Dutch National Randomised Study of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography as a Triage Tool for Pelvic Lymph Node Dissection in Patients Undergoing Radical Prostatectomy. European Urology Focus, 2022, 8. 1198-1203.	1.6	3
485	Unfavorable Clinicopathological Features in Radical Prostatectomy Patients Who Were Spared Pelvic Lymphadenectomy. Acta Clinica Croatica, 2018, 57, 61-65.	0.1	0
486	THE ROLE OF LYMPHADENECTOMY IN PROSTATE CANCER PATIENTS Acta Clinica Croatica, 2019, 58, 24-35.	0.1	0
488	Contemporary Pathological Stage Distribution After Radical Prostatectomy in North American High-Risk Prostate Cancer Patients. Clinical Genitourinary Cancer, 2022, 20, e380-e389.	0.9	5
489	Utility of Lymphadenectomy in Prostate Cancer: Where Do We Stand?. Journal of Clinical Medicine, 2022, 11, 2343.	1.0	2
490	Patients with Positive Lymph Nodes after Radical Prostatectomy and Pelvic Lymphadenectomy—Do We Know the Proper Way of Management?. Cancers, 2022, 14, 2326.	1.7	2

#	Article	IF	CITATIONS
491	The Correlation Between Platelet Count and Survival in Prostate Cancer. Research and Reports in Urology, 2022, Volume 14, 193-202.	0.6	2
492	The role of prostate-specific membrane antigen PET/computed tomography in the management of prostate cancer patients: could we ask for more?. Current Opinion in Urology, 2022, 32, 269-276.	0.9	2
493	Integration of magnetic resonance imaging into prostate cancer nomograms. Therapeutic Advances in Urology, 2022, 14, 175628722210963.	0.9	0
495	Predictive role of node-rads score in patients with prostate cancer candidates for radical prostatectomy with extended lymph node dissection: comparative analysis with validated nomograms. Prostate Cancer and Prostatic Diseases, 2023, 26, 379-387.	2.0	9
496	Development of a novel nomogram to identify the candidate to extended pelvic lymph node dissection in patients who underwent mpMRI and target biopsy only. Prostate Cancer and Prostatic Diseases, 2023, 26, 388-394.	2.0	8
497	Magnetic Resonance Imaging-Targeted Biopsy and Pretherapeutic Prostate Cancer Risk Assessment: a Systematic Review. Progres En Urologie, 2022, 32, 32/6S3-32/6S18.	0.3	0
498	The sentinel node with technetium-99m for prostate cancer. A safe and mature new gold standard?. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2023, 67, .	0.4	2
499	Preoperative prediction of pelvic lymph nodes metastasis in prostate cancer using an ADC-based radiomics model: comparison with clinical nomograms and PI-RADS assessment. Abdominal Radiology, 0, , .	1.0	5
500	Performance evaluation of the Partin Table (2007), in a current ecuadorian sample. Revista Mexicana De Urologia, 2022, 82, 1-10.	0.0	0
501	Significance of pelvic lymph node dissection during radical prostatectomy in high-risk prostate cancer patients receiving neoadjuvant chemohormonal therapy. Scientific Reports, 2022, 12, .	1.6	2
502	Prognostic Impact of Lymphatic Invasion in Patients with High-Risk Prostate Cancer after Robot-Assisted Radical Prostatectomy and Extended Lymph Node Dissection: A Single-Institution Prospective Cohort Study. Cancers, 2022, 14, 3466.	1.7	3
503	Predictive Value of Cribriform and Intraductal Carcinoma for the Nomogram-based Selection of Prostate Cancer Patients for Pelvic Lymph Node Dissection. Urology, 2022, 168, 156-164.	0.5	1
504	Interlaboratory Cleason grading variation affects treatment: a Dutch historic cohort study in 30 509 patients with prostate cancer. Journal of Clinical Pathology, 2023, 76, 690-697.	1.0	2
505	Prostate-specific membrane antigen Radioguided Surgery to Detect Nodal Metastases in Primary Prostate Cancer Patients Undergoing Robot-assisted Radical Prostatectomy and Extended Pelvic Lymph Node Dissection: Results of a Planned Interim Analysis of a Prospective Phase 2 Study. European Urology, 2022, 82, 411-418.	0.9	41
506	Assessing the accuracy of [18F]PSMA-1007 PET/CT for primary staging of lymph node metastases in intermediate- and high-risk prostate cancer patients. EJNMMI Research, 2022, 12, .	1.1	4
508	Current Imaging Modalities to Assess Prostate Cancer. , 2022, , 117-143.		Ο
509	Effect of Peritoneal Fixation (PerFix) on Lymphocele Formation in Robot-assisted Radical Prostatectomy with Pelvic Lymphadenectomy: Results of a Randomized Prospective Trial. European Urology, 2023, 83, 154-162.	0.9	12
510	Free-indocyanine green-guided pelvic lymph node dissection during radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 489.e19-489.e26.	0.8	8

#	Article	IF	CITATIONS
511	Magnetic resonance imaging target fusion biopsy vs. transrectal ultrasound-guided biopsy - A comparative study of ISUP score upgrading risk in the ï¬nal radical prostatectomy specimen. Archivio Italiano Di Urologia Andrologia, 2022, 94, 278-284.	0.4	1
512	From past to future: Bibliometric analysis of global research productivity on nomogram (2000–2021). Frontiers in Public Health, 0, 10, .	1.3	28
513	Prognostic Value of Albumin to Globulin Ratio in Non-Metastatic and Metastatic Prostate Cancer Patients: A Meta-Analysis and Systematic Review. International Journal of Molecular Sciences, 2022, 23, 11501.	1.8	5
514	Selecting lymph node–positive patients for adjuvant therapy after radical prostatectomy and extended pelvic lymphadenectomy: An outcome analysis of 100 node-positive patients managed without adjuvant therapy. Current Urology, 0, Publish Ahead of Print, .	0.4	0
515	Hemopatch to Prevent Lymphatic Leak after Robotic Prostatectomy and Pelvic Lymph Node Dissection: A Randomized Controlled Trial. Cancers, 2022, 14, 4476.	1.7	0
516	Neuraxial anesthesia versus general anesthesia in patients undergoing three-dimensional laparoscopic radical prostatectomy: Preliminary results of a prospective comparative study. Asian Journal of Urology, 2023, 10, 329-336.	0.5	2
517	Clinical significance of limited and extended pelvic lymph node dissection during robotâ€assisted radical prostatectomy for patients with localized prostate cancer: A retrospective, propensity score matching analysis. International Journal of Urology, 2023, 30, 168-175.	0.5	1
518	Perioperative morbidity of radical prostatectomy after intensive neoadjuvant androgen blockade in men with high-risk prostate cancer: results of phase II trial compared to a control group. Clinical Genitourinary Cancer, 2022, , .	0.9	2
519	A Nomogram for Predicting Prostate Cancer with Lymph Node Involvement in Robot-Assisted Radical Prostatectomy Era: A Retrospective Multicenter Cohort Study in Japan (The MSUG94 Group). Diagnostics, 2022, 12, 2545.	1.3	3
521	French AFU Cancer Committee Guidelines - Update 2022-2024: prostate cancer - Diagnosis and management of localised disease. Progres En Urologie, 2022, 32, 1275-1372.	0.3	15
522	Transperitoneal Robot-Assisted Laparoscopic Radical Prostatectomy Retzius-Sparing Approach: Yonsei Technique. , 2022, , 169-177.		0
523	Extended Lymphadenectomy Technique. , 2022, , 227-233.		0
524	Predictive Models in Prostate Cancer. , 2022, , 217-225.		0
525	Retzius-sparing vs. standard robot-assisted radical prostatectomy for clinically localised prostate cancer: a comparative study. Prostate Cancer and Prostatic Diseases, 2023, 26, 568-574.	2.0	7
526	Pelvic Lymphadenectomy May Not Improve Biochemical Recurrence-Free Survival in Patients with Prostate Cancer Treated with Robot-Assisted Radical Prostatectomy in Japan (The MSUG94 Group). Cancers, 2022, 14, 5803.	1.7	3
527	Using PSMA imaging for prognostication in localized and advanced prostate cancer. Nature Reviews Urology, 2023, 20, 23-47.	1.9	20
528	Comparative Prospective and Longitudinal Analysis on the Platelet-to-Lymphocyte, Neutrophil-to-Lymphocyte, and Albumin-to-Globulin Ratio in Patients with Non-Metastatic and Metastatic Prostate Cancer. Current Oncology, 2022, 29, 9474-9500.	0.9	4
529	Impacto bioquÃmico de la omisión de la linfadenectomÃa en cáncer de próstata: validación de las tablas de Partin. Revista Mexicana De Urologia, 2023, 82, 1-10.	0.0	0

#	Article	IF	CITATIONS
532	Long-Term Oncological Outcomes of High-Risk Prostate Cancer defined by Histopathological Examination. Journal of Nippon Medical School, 2023, , .	0.3	0
533	Prognostic role of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with non-metastatic and metastatic prostate cancer: A meta-analysis and systematic review. Asian Journal of Urology, 2023, , .	0.5	1
534	Sentinel Node Procedure to Select Clinically Localized Prostate Cancer Patients with Occult Nodal Metastases for Whole Pelvis Radiotherapy. European Urology Open Science, 2023, 49, 80-89.	0.2	8
535	The combination of prostate MRI PI-RADS scoring system and a genomic classifier is associated with pelvic lymph node metastasis at the time of radical prostatectomy. British Journal of Radiology, 2023, 96, .	1.0	0
536	Predictor Factors for the Detection of Positive Nodes in Patients Undergoing Radical Prostatectomy and Lymph Node Dissection. , 2023, 1, 19-24.		0
537	Radikal prostatektomi yapılan hastalarda lenf nodu invazyonunu öngören preoperatif nomogramların karşılaştırılması. Endouroloji Bulteni, 2023, 15, 16-22.	0.0	0
538	Comparison of neoadjuvant chemohormonal therapy vs. extended pelvic lymph-node dissection in high-risk prostate cancer treated with robot-assisted radical prostatectomy. Scientific Reports, 2023, 13, .	1.6	2
539	Development and External Validation of a Machine Learning Model for Prediction of Lymph Node Metastasis in Patients with Prostate Cancer. European Urology Oncology, 2023, 6, 501-507.	2.6	3
540	External Validation of Briganti and Memorial Sloan-Kettering Cancer Centre Nomograms for Predicting Lymph Node Invasion in the Indian Cohort of Patients with Prostate Cancer. Indian Journal of Surgical Oncology, 0, , .	0.3	1
541	The Hunt for Lymph Nodes: Is Total Submission of Standard and Extended-Template Pelvic Lymph Node Dissections Necessary for Detecting Metastatic Prostate Cancer?. Archives of Pathology and Laboratory Medicine, 2023, , .	1.2	0
	Comparison of Four Validated Nomograms (Memorial Sloan Kettering Cancer Center, Briganti 2012,) Tj ETQq0 0	0 rgBT /Ov	verlock 10 Tf
542	for Radical Prostatectomy and Extended Pelvic Lymph Node Dissection: Clinical Experience and Review of the Literature. Cancers, 2023, 15, 1683.	1.7	1
543	Complications of extraperitoneal robot-assisted radical prostatectomy in high-risk prostate cancer: A single high-volume center experience. Frontiers in Surgery, 0, 10, .	0.6	6
563	PSMA PET/CT and PET/MRI in primary staging of prostate cancer and its effect on patient management. Clinical and Translational Imaging, 0, , .	1.1	0